

In the Claims:

In compliance with the voluntary practice guidelines for making amendments, Applicants present all pending claims with status indicators.

Nk.
Please cancel claims 54-57 and 75-76 without prejudice to pursue the subject matter of these claims in an application to be filed in the future.

Please amend claim 53 and 73 as follows:

1. (Cancelled)
53. (Currently Amended) A method for inducing ~~an~~ a cellular immune response in a human subject directed to a PSCA protein of Fig. 1B (SEQ ID NO:2) in a subject having a cancer expressing a Prostate Stem Cell Antigen (PSCA) protein, comprising administering to the subject a PSCA protein fragment comprising a portion of a PSCA protein of Fig. 1B (SEQ ID NO:2) ~~or Fig 2 (SEQ ID NO:4).~~
- 54 to 57. (Cancelled)
58. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.
59. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.

RECEIVED

JUL 24 2003

TECH CENTER 1600/2900

- 26.
60. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.
 61. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.
 62. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.
 63. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.
 64. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.
 65. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 50 through 64 as described in SEQ ID NO:2.
 66. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 67 through 81 as described in SEQ ID NO:2.

- Nk
67. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 21 through 99 as described in SEQ ID NO:2.
 68. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 71 through 82 as described in SEQ ID NO:2.
 69. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.
 70. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.
 71. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.
 72. (Previously amended) The method of claim 53, wherein the PSCA protein fragment consists of amino acid residues 85 through 98 as described in SEQ ID NO:2.
 73. (Currently amended) The method of claim 53, wherein the cancer cells expressing the PSCA protein is prostate cancer, prostate cancer metastasized to bone, ovarian cancer, tonsil cancer, ~~bladder cancer~~, stomach cancer, kidney cancer, testicular cancer, small intestinal cancer, colon cancer, or pancreatic cancer.

Wk

74. (Previously Added) The method of claim 53, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO:2.
75. (Cancelled)
76. (Cancelled)
77. (New) The method of claim 53 wherein the administering step further comprises administering dendritic cells.
78. (New) A method for inducing an immune response in a mammalian subject, comprising administering to the subject a PSCA protein fragment comprising a portion of a PSCA protein of Fig. 1B (SEQ ID NO:2).
79. (New) The method of claim 78 wherein the immune response is a humoral response, whereby an antibody is produced.
80. (New) The method of claim 78, wherein the subject is a human.
81. (New) The method of claim 78, wherein the subject is a sheep, rat, dog, cat, pig, horse, or mouse.
82. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 2 through 50 as described in SEQ ID NO:2.
83. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 123 as described in SEQ ID NO:2.
84. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 109 as described in SEQ ID NO:2.

- Ne
85. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 98 as described in SEQ ID NO:2.
 86. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 22 through 99 as described in SEQ ID NO:2.
 87. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 50 as described in SEQ ID NO:2.
 88. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 85 as described in SEQ ID NO:2.
 89. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 50 through 64 as described in SEQ ID NO:2.
 90. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 67 through 81 as described in SEQ ID NO:2.
 91. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 21 through 99 as described in SEQ ID NO:2.
 92. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 71 through 82 as described in SEQ ID NO:2.
 93. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 99 as described in SEQ ID NO:2.
 94. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 18 through 50 as described in SEQ ID NO:2.

Applicant: Robert E. Reiter, et al.

U.S. Serial No.: 09/854,811

Filed: May 14, 2001

Page 8

- W 6
95. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 46 through 98 as described in SEQ ID NO:2.
96. (New) The method of claim 78, wherein the PSCA protein fragment consists of amino acid residues 85 through 98 as described in SEQ ID NO:2.
97. (New) The method of claim 78, wherein the protein fragment consists of amino acid residues 1 through 123 as described in SEQ ID NO: 2.
-